Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rein Therapeutics Inc. (RNTX : NSDQ)

• Company Description    Rein Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein Therapeutics, formerly known as Aileron Therapeutics Inc., is based in AUSTIN, Texas. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $1.16 Daily Weekly Monthly 20 Day Moving Average: 247,000 shares Shares Outstanding: 26.29 (millions) Market Capitalization: $30.49 (millions) Beta: 1.31 52 Week High: $3.50 52 Week Low: $1.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.55% -16.41% 12 Week -15.33% -16.69% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12407 N. MOPAC EXPY. SUITE 250 #390 - AUSTIN,TX 78758 USA ph: 737-802-1989 fax: - rein@argotpartners.com http://www.reintx.com

• General Corporate Information    Officers Brian Windsor - President; Chief Executive Officer and Director Josef H. Von Rickenbach - Chairman of the Board of Directors Timothy M. Cunningham - Interim Chief Financial Officer Manuel C. Aivado - Director Reinhard J. Ambros - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00887A204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/06/26 Share - Related Items Shares Outstanding: 26.29 Most Recent Split Date: 11.00 (0.05:1) Beta: 1.31 Market Capitalization: $30.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 22.81 Price/Cash Flow: 2.59 Price / Sales: - EPS Growth vs. Year Ago Period: 22.22% vs. Previous Quarter: 25.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -510.35 06/30/25 - -141.11 ROA 12/31/25 - - 09/30/25 - -40.77 06/30/25 - -33.83 Current Ratio 12/31/25 - - 09/30/25 - 0.90 06/30/25 - 0.86 Quick Ratio 12/31/25 - - 09/30/25 - 0.90 06/30/25 - 0.86 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.05 06/30/25 - 0.13 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©